Auxier Asset Management Sells 525 Shares of Pfizer Inc. (NYSE:PFE)

Auxier Asset Management reduced its position in Pfizer Inc. (NYSE:PFE) by 0.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 68,253 shares of the biopharmaceutical company’s stock after selling 525 shares during the period. Auxier Asset Management’s holdings in Pfizer were worth $1,975,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Olistico Wealth LLC purchased a new stake in shares of Pfizer during the 2nd quarter valued at approximately $25,000. Gladius Capital Management LP lifted its position in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares in the last quarter. MFA Wealth Advisors LLC bought a new position in shares of Pfizer in the second quarter worth $29,000. Quarry LP purchased a new position in shares of Pfizer in the second quarter valued at $31,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Pfizer during the 2nd quarter valued at $34,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Citigroup assumed coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price on the stock. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Sanford C. Bernstein initiated coverage on Pfizer in a research report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective on the stock. Finally, Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.92.

Pfizer Stock Up 0.2 %

Shares of NYSE PFE opened at $25.83 on Friday. The stock has a market capitalization of $146.38 billion, a P/E ratio of 34.91, a PEG ratio of 0.70 and a beta of 0.67. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The firm’s 50 day simple moving average is $27.89 and its two-hundred day simple moving average is $28.51. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the previous year, the firm posted ($0.17) earnings per share. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.50%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.